Stereoselective ring oxidation of propranolol in man.
Authors:
- T WalleTWT Walle
- Uk WalleUWUk Walle
- Mj WilsonMWMj Wilson
- Tc FaganTFTc Fagan
- Te GaffneyTGTe Gaffney
Open Access
- 1 November 1984
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 18 (5) , 741-748
Abstract
The objective of this study was to elucidate stereoselective mechanisms of propranolol metabolism in man. Five normal subjects were given single 80 mg oral doses of deuterium‐labeled pseudoracemates of propranolol, and the stereochemical composition of propranolol and its major metabolites in urine was determined by GC/MS. The (‐)/(+)‐ enantiomer ratios for unchanged propranolol, 1.50 +/‐ 0.10 (mean +/‐ s.e. mean), and propranolol glucuronide, 1.76 +/‐ 0.10, were similar to previous findings in plasma. All products of side‐chain oxidation also consisted mainly of the (‐)‐enantiomer, with an overall (‐)/(+) ratio of 1.61 +/‐ 0.11. A (‐)/(+) ratio of 1.04 +/‐ 0.17 for 4‐ hydroxypropranolol did not indicate stereoselectivity in ring oxidation. However, the ratio for its glucuronic acid conjugate of 1.78 +/‐ 0.19 and for its sulphate conjugate of 0.27 +/‐ 0.03 suggested stereoselectivity in either the glucuronidation or sulphation of 4‐ hydroxypropranolol, or both. When the stereoselectivity in these secondary pathways was taken into consideration, the overall ring oxidation strongly favoured (+)‐propranolol with a (‐)/(+)‐enantiomer ratio of 0.59 +/‐ 0.09. The composite observations of the stereochemistry of propranolol metabolism in man are consistent with stereoselective ring oxidation of (+)‐propranolol, leading to a greater bioavailability of the pharmacologically more active (‐)‐propranolol and subsequent preferential side‐chain oxidation and glucuronidation of this enantiomer.Keywords
This publication has 24 references indexed in Scilit:
- Plasma levels of (+) and (−)−propranolol and 4‐hydroxypropranolol after administration of racemic (+/‐)‐propranolol in man.British Journal of Clinical Pharmacology, 1982
- Stereoselective Disposition and Glucuronidation of Propranolol in HumansJournal of Pharmaceutical Sciences, 1982
- Ring-hydroxylated propranolol: synthesis and .beta.-receptor antagonist and vasodilating activities of the seven isomersJournal of Medicinal Chemistry, 1981
- 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranololClinical Pharmacology & Therapeutics, 1980
- Direct measurement of propranolol bioavailability during accumulation to steady‐state.British Journal of Clinical Pharmacology, 1978
- Disposition of propranolol V. Drug accumulation and steady‐state concentrations during chronic oral administration in manClinical Pharmacology & Therapeutics, 1973
- The Disposition of PropranololPharmacology, 1972
- Pharmacology of 4‐hydroxypropranolol, a metabolite of propranololBritish Journal of Pharmacology, 1971
- Plasma Propranolol Levels in the Quantitative Assessment of β-adrenergic Blockade in ManBMJ, 1970
- The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmiasBritish Journal of Pharmacology, 1968